EQS-News: Marinomed Biotech AG / Key word(s): Market Launch
Marinomed Biotech AG: Launch of new allergen-blocking Carragelose product in Austria and market entry in Mexico

11.04.2024 / 07:45 CET/CEST
The issuer is solely responsible for the content of this announcement.


Marinomed Biotech AG: Launch of new allergen-blocking Carragelose product in Austria and market entry in Mexico

• Launch of new allergen-blocking nasal spray in Austria for the treatment of hay fever complements existing OTC product portfolio
• Partner M8 Pharmaceuticals launches Carragelose nasal spray for the treatment of viral respiratory infections in Mexico
• Further value maximization and revenue potential for Carragelose asset

Korneuburg, Austria, 11 April 2024 – Marinomed Biotech AG (VSE:MARI) today announces the expansion of its Carragelose product portfolio with new launches in
Austria and Mexico, paving the way for targeting new indications and access to key markets. A new nasal spray formulation for the treatment of the symptoms of hay
fever caused by grass pollen allergy has been launched by Marinomed’s Austrian distribution partner Sigmapharm under the brand name COLDAMARIS Allergie. Offering
both symptom prevention and relief of allergic symptoms such as dryness in the nasal cavity, runny or blocked nose, itching and sneezing, this market entry
perfectly coincides with the peak of this year’s allergy season. The launch of the allergen-blocking nasal spray also represents an important landmark in the
expansion of the established Carragelose portfolio from blocking viruses to allergic indications, providing year-round revenue generation beyond the typical cold

Furthermore, following the successful market approval of a Carragelose nasal spray in Mexico by its distribution partner M8 Pharmaceuticals (an Acino company) last
summer, the product is now available under the brand name Barlo®. Targeting the Mexican market, which is Latin America’s second largest pharmaceutical market, this
launch represents a significant revenue potential.

“With the market launch of our first Carragelose product in the Immunology segment and the product launch in Mexico, the second largest pharmaceutical market in
Latin America, we have set important milestones in the ongoing expansion of our Carragelose portfolio. We are well on our way to close further geographic gaps in
Europe, the Middle East and Latin America with new and existing partners and are now also targeting new indications. This makes us less dependent on the cold
season, enables year-round sales and lets us expect new growth opportunities”, Andreas Grassauer, CEO of Marinomed, comments. “In addition to these developments,
the launch of the Carragelose-containing eye drops and the filing for approval with Procter & Gamble in the U.S. are making good progress as well.”

About Carragelose®

Carragelose® is a sulfated polymer from red seaweed and a unique, broadly active virus- and allergen-blocking compound. It is known as a gentle, effective, and
safe prevention and treatment of various viral respiratory infections. Several clinical and preclinical studies have shown that Carragelose® forms a protective
layer on the mucosa that prevents viruses from infecting cells. Laboratory and clinical data have demonstrated that Carragelose® can also inhibit the spreading of
SARS-CoV-2.^[1][1],[2][2] Marinomed is the holder of the IP rights and has licensed Carragelose® for marketing in Europe, North America, Australia, and parts of
Asia and Latin America. Marinomed’s portfolio of Carragelose®-containing nasal sprays and oral products can be accessed at
[3] https://www.carragelose.com/en/portfolio/launched-products, scientific publications on Carragelose® at [4] https://www.carragelose.com/en/publications.

About Marinomed Biotech AG

Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline and globally marketed therapeutics. The Company develops
innovative patent-protected products in the therapeutic areas immunology and virology based on the platform Marinosolv® and the virus-blocking activity of
Carragelose®. The Marinosolv® technology improves the solubility and bioavailability of hardly soluble compounds and is used to develop new therapeutics for
autoreactive immune disorders. The virology segment includes Carragelose®-based over-the-counter (OTC) products to prevent and treat respiratory viral infections
that are partnered in more than 40 countries. The Company is headquartered in Korneuburg, Austria, and is listed on the prime market of the Vienna Stock Exchange
(VSE:MARI). For further information, please visit: [5] https://www.marinomed.com.

For further inquiries contact:

Marinomed Biotech AG International Media Contact
PR & IR: Lucia Ziegler Metrum Communications: Eva Ruppnig
T: +43 2262 90300 158 T: +43 664 4065744
E-Mail: [6]pr@marinomed.com E-Mail: [8]marinomed@metrum.at
E-Mail: [7]ir@marinomed.com  


This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG
about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to
differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of
Marinomed Biotech AG may be identified by the context of such statements or words such as “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”,
“project” and “target”. Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update,
review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise.
Marinomed, Marinosolv® and Carragelose® are registered trademarks of Marinomed Biotech AG. These trademarks may be owned or licensed in select locations only.

[9]^[1]  [10]https://www.dovepress.com/efficacy-of-a-nasal-spray-containing-iota-carrageenan-in-the-postexpos-peer-reviewed-fulltext-article-IJGM



11.04.2024 CET/CEST This Corporate News was distributed by EQS Group AG. www.eqs.com


Language: English
Company: Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg
Phone: +43 2262 90300
E-mail: office@marinomed.com
Internet: www.marinomed.com
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt,
Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange
(Official Market)
EQS News ID: 1877827

End of News EQS News Service

1877827  11.04.2024 CET/CEST


Visible links
1. file:///appl/crsred1/tmp/HTML-FormatExternal-DdsUsf.html#_edn1
2. file:///appl/crsred1/tmp/HTML-FormatExternal-DdsUsf.html#_edn2
3. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=bd2a3dda556ab52fe6b2a10b732e7834&application_id=1877827&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
4. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=43c84c05c837223116d24f9889459559&application_id=1877827&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
5. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=b364e041c58da1aeff9758a10a9b0152&application_id=1877827&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
6. pr@marinomed.com
7. ir@marinomed.com
8. marinomed@metrum.at
9. file:///appl/crsred1/tmp/HTML-FormatExternal-DdsUsf.html#_ednref1
10. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=33ccd3741e11d696674979569046f638&application_id=1877827&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
11. file:///appl/crsred1/tmp/HTML-FormatExternal-DdsUsf.html#_ednref2
12. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=21dfc7afdd676fd13f5e421e04701661&application_id=1877827&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news